首頁 > 市場調查報告書 > 製藥

神經疾病孤兒藥

市場調查報告書

商品編碼

1420997

格林-巴利綜合症市場（治療方法：靜脈注射免疫球蛋白、血漿交換等；給藥途徑：口服和腸胃外）- 全球行業分析、規模、佔有率、成長、趨勢和預測，2023-2031 年

Guillain-Barre Syndrome Market (Therapeutics: Intravenous Immunoglobulin, Plasma Exchange, and Others; and Route of Administration: Oral and Parenteral) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

出版日期: 2023年12月22日 | 出版商:

Transparency Market Research | 英文 194 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

格林巴利症候群市場 - 報告範圍

TMR 關於全球格林巴利綜合症市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了全球格林巴利綜合症的收入2017-2031 年巴利綜合症市場，以2023 年為基準年，2031 年為預測年。該報告也提供了2023年至2031年全球格林-巴利症候群市場的年複合成長率（CAGR %）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解格林巴利綜合症市場。

市場概況
2023年市場價值	5.913 億美元
2031 年市場價值	8.902 億美元
CAGR	4.7%

該報告深入研究了全球格林巴利症候群市場的競爭格局。全球格林巴利綜合症市場的主要參與者已被確定，並且每一位參與者都已根據各種屬性進行了分析。公司概述、財務狀況、最新發展和 SWOT 是本報告中介紹的全球格林巴利綜合症市場參與者的屬性。

TMR's report on the global Guillain-Barre Syndrome market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Guillain-Barre Syndrome market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Guillain-Barre Syndrome market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Guillain-Barre Syndrome market.

Market Snapshot
Market Value in 2023	US$ 591.3 Mn
Market Value in 2031	US$ 890.2 Mn
CAGR	4.7%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Guillain-Barre Syndrome market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Guillain-Barre Syndrome market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Guillain-Barre Syndrome market.

The report delves into the competitive landscape of the global Guillain-Barre Syndrome market. Key players operating in the global Guillain-Barre Syndrome market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Guillain-Barre Syndrome market profiled in this report.

Key Questions Answered in Global Guillain-Barre Syndrome Market Report:

What is the sales/revenue generated by Guillain-Barre Syndrome across all regions during the forecast period?
What are the opportunities in the global Guillain-Barre Syndrome market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Guillain-Barre Syndrome Market - Research Objectives and Research Approach

The comprehensive report on the global Guillain-Barre Syndrome market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Guillain-Barre Syndrome market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Guillain-Barre Syndrome market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Guillain-Barre Syndrome Market

4. Market Overview

4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Guillain-Barre Syndrome Market Analysis and Forecast, 2017-2031

5. Key Insights

5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Guillain-Barre Syndrome Market Analysis and Forecast, by Therapeutics

6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Therapeutics, 2017-2031
- 6.3.1. Intravenous Immunoglobulin
- 6.3.2. Plasma Exchange
- 6.3.3. Others
6.4. Market Attractiveness Analysis, by Therapeutics

7. Global Guillain-Barre Syndrome Market Analysis and Forecast, by Route of Administration

7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2017-2031
- 7.3.1. Oral
- 7.3.2. Parenteral
7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Guillain-Barre Syndrome Market Analysis and Forecast, by Distribution Channel

8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 8.3.1. Hospitals
- 8.3.2. Pharmacies
- 8.3.3. Retail Pharmacies
- 8.3.4. Others
8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Guillain-Barre Syndrome Market Analysis and Forecast, by Region

9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. South America
- 9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Guillain-Barre Syndrome Market Analysis and Forecast

10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Therapeutics, 2017-2031
- 10.3.1. Intravenous Immunoglobulin
- 10.3.2. Plasma Exchange
- 10.3.3. Others
10.4. Market Value Forecast, by Route of Administration, 2017-2031
- 10.4.1. Oral
- 10.4.2. Parenteral
10.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 10.5.1. Hospitals
- 10.5.2. Pharmacies
- 10.5.3. Retail Pharmacies
- 10.5.4. Others
10.6. Market Value Forecast, by Country, 2017-2031
- 10.6.1. U.S.
- 10.6.2. Canada
10.7. Market Attractiveness Analysis
- 10.7.1. By Therapeutics
- 10.7.2. By Route of Administration
- 10.7.3. By Distribution Channel
- 10.7.4. By Country

11. Europe Guillain-Barre Syndrome Market Analysis and Forecast

11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Therapeutics, 2017-2031
- 11.3.1. Intravenous Immunoglobulin
- 11.3.2. Plasma Exchange
- 11.3.3. Others
11.4. Market Value Forecast, by Route of Administration, 2017-2031
- 11.4.1. Oral
- 11.4.2. Parenteral
11.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 11.5.1. Hospitals
- 11.5.2. Pharmacies
- 11.5.3. Retail Pharmacies
- 11.5.4. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.6.1. Germany
- 11.6.2. U.K.
- 11.6.3. France
- 11.6.4. Italy
- 11.6.5. Spain
- 11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
- 11.7.1. By Therapeutics
- 11.7.2. By Route of Administration
- 11.7.3. By Distribution Channel
- 11.7.4. By Country/Sub-region

12. Asia Pacific Guillain-Barre Syndrome Market Analysis and Forecast

12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Therapeutics, 2017-2031
- 12.3.1. Intravenous Immunoglobulin
- 12.3.2. Plasma Exchange
- 12.3.3. Others
12.4. Market Value Forecast, by Route of Administration, 2017-2031
- 12.4.1. Oral
- 12.4.2. Parenteral
12.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 12.5.1. Hospitals
- 12.5.2. Pharmacies
- 12.5.3. Retail Pharmacies
- 12.5.4. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.6.1. China
- 12.6.2. Japan
- 12.6.3. India
- 12.6.4. Australia & New Zealand
- 12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
- 12.7.1. By Therapeutics
- 12.7.2. By Route of Administration
- 12.7.3. By Distribution Channel
- 12.7.4. By Country/Sub-region

13. South America Guillain-Barre Syndrome Market Analysis and Forecast

13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Therapeutics, 2017-2031
- 13.3.1. Intravenous Immunoglobulin
- 13.3.2. Plasma Exchange
- 13.3.3. Others
13.4. Market Value Forecast, by Route of Administration, 2017-2031
- 13.4.1. Oral
- 13.4.2. Parenteral
13.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 13.5.1. Hospitals
- 13.5.2. Pharmacies
- 13.5.3. Retail Pharmacies
- 13.5.4. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.6.1. Brazil
- 13.6.2. Mexico
- 13.6.3. Rest of South America
13.7. Market Attractiveness Analysis
- 13.7.1. By Therapeutics
- 13.7.2. By Route of Administration
- 13.7.3. By Distribution Channel
- 13.7.4. By Country/Sub-region

14. Middle East & Africa Guillain-Barre Syndrome Market Analysis and Forecast

14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Therapeutics, 2017-2031
- 14.3.1. Intravenous Immunoglobulin
- 14.3.2. Plasma Exchange
- 14.3.3. Others
14.4. Market Value Forecast, by Route of Administration, 2017-2031
- 14.4.1. Oral
- 14.4.2. Parenteral
14.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 14.5.1. Hospitals
- 14.5.2. Pharmacies
- 14.5.3. Retail Pharmacies
- 14.5.4. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.6.1. GCC Countries
- 14.6.2. South Africa
- 14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
- 14.7.1. By Therapeutics
- 14.7.2. By Route of Administration
- 14.7.3. By Distribution Channel
- 14.7.4. By Country/Sub-region

15. Competition Landscape

15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
- 15.3.1. Grifols S.A
  - 15.3.1.1. Company Overview
  - 15.3.1.2. Product Portfolio
  - 15.3.1.3. SWOT Analysis
  - 15.3.1.4. Financial Overview
  - 15.3.1.5. Strategic Overview
- 15.3.2. CSL Behring LLC
  - 15.3.2.1. Company Overview
  - 15.3.2.2. Product Portfolio
  - 15.3.2.3. SWOT Analysis
  - 15.3.2.4. Financial Overview
  - 15.3.2.5. Strategic Overview
- 15.3.3. Shire plc
  - 15.3.3.1. Company Overview
  - 15.3.3.2. Product Portfolio
  - 15.3.3.3. SWOT Analysis
  - 15.3.3.4. Financial Overview
  - 15.3.3.5. Strategic Overview
- 15.3.4. Octapharma AG
  - 15.3.4.1. Company Overview
  - 15.3.4.2. Product Portfolio
  - 15.3.4.3. SWOT Analysis
  - 15.3.4.4. Financial Overview
  - 15.3.4.5. Strategic Overview
- 15.3.5. Nihon Pharmaceutical Co.,Ltd
  - 15.3.5.1. Company Overview
  - 15.3.5.2. Product Portfolio
  - 15.3.5.3. SWOT Analysis
  - 15.3.5.4. Financial Overview
  - 15.3.5.5. Strategic Overview
- 15.3.6. Akari Therapeutics, PLC
  - 15.3.6.1. Company Overview
  - 15.3.6.2. Product Portfolio
  - 15.3.6.3. SWOT Analysis
  - 15.3.6.4. Financial Overview
  - 15.3.6.5. Strategic Overview
- 15.3.7. China Biological Products Holdings,Inc.
  - 15.3.7.1. Company Overview
  - 15.3.7.2. Product Portfolio
  - 15.3.7.3. SWOT Analysis
  - 15.3.7.4. Financial Overview
  - 15.3.7.5. Strategic Overview
- 15.3.8. Biotest AG
  - 15.3.8.1. Company Overview
  - 15.3.8.2. Product Portfolio
  - 15.3.8.3. SWOT Analysis
  - 15.3.8.4. Financial Overview
  - 15.3.8.5. Strategic Overview
- 15.3.9. Kedrion S.p.A
  - 15.3.9.1. Company Overview
  - 15.3.9.2. Product Portfolio
  - 15.3.9.3. SWOT Analysis
  - 15.3.9.4. Financial Overview
  - 15.3.9.5. Strategic Overview

簡介目錄圖表

List of Tables

Table 01: Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 02: Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 03: Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 04: Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Region, 2017-2031
Table 05: North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country, 2017-2031
Table 06: North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 07: North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 08: North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 09: Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 10: Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 11: Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 12: Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 13: Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 15: Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 16: Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 17: South America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 18: South America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 19: South America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 20: South America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 21: Middle East & Africa Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Middle East & Africa Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 23: Middle East & Africa Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 24: Middle East & Africa Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

Figure 01: Global Guillain-Barre Syndrome Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global Guillain-Barre Syndrome Market Revenue (US$ Mn), by Therapeutics, 2022
Figure 03: Global Guillain-Barre Syndrome Market Value Share, by Therapeutics, 2022
Figure 04: Global Guillain-Barre Syndrome Market Revenue (US$ Mn), by Route of Administration, 2022
Figure 05: Global Guillain-Barre Syndrome Market Value Share, by Route of Administration, 2022
Figure 06: Global Guillain-Barre Syndrome Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 07: Global Guillain-Barre Syndrome Market Value Share, by Distribution Channel, 2022
Figure 08: Global Guillain-Barre Syndrome Market Value Share, by Region, 2022
Figure 09: Global Guillain-Barre Syndrome Market Value (US$ Mn) Forecast, 2017-2031
Figure 10: Global Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 11: Global Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2023-2031
Figure 12: Global Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 13: Global Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 14: Global Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 15: Global Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 16: Global Guillain-Barre Syndrome Market Value Share Analysis, by Region, 2022 and 2031
Figure 17: Global Guillain-Barre Syndrome Market Attractiveness Analysis, by Region, 2023-2031
Figure 18: North America Guillain-Barre Syndrome Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 19: North America Guillain-Barre Syndrome Market Attractiveness Analysis, by Country, 2023-2031
Figure 20: North America Guillain-Barre Syndrome Market Value Share Analysis, by Country, 2022 and 2031
Figure 21: North America Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 22: North America Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 23: North America Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 24: North America Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2023-2031
Figure 25: North America Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 26: North America Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 27: Europe Guillain-Barre Syndrome Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
Figure 28: Europe Guillain-Barre Syndrome Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 29: Europe Guillain-Barre Syndrome Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 30: Europe Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 31: Europe Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 32: Europe Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 33: Europe Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2023-2031
Figure 34: Europe Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 35: Europe Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 36: Asia Pacific Guillain-Barre Syndrome Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
Figure 37: Asia Pacific Guillain-Barre Syndrome Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 38: Asia Pacific Guillain-Barre Syndrome Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 39: Asia Pacific Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 40: Asia Pacific Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 41: Asia Pacific Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 42: Asia Pacific Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2023-2031
Figure 43: Asia Pacific Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 44: Asia Pacific Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 45: South America Guillain-Barre Syndrome Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
Figure 46: South America Guillain-Barre Syndrome Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 47: South America Guillain-Barre Syndrome Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 48: South America Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 49: South America Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 50: South America Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 51: South America Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2023-2031
Figure 52: South America Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 53: South America Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 54: Middle East & Africa Guillain-Barre Syndrome Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
Figure 55: Middle East & Africa Guillain-Barre Syndrome Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 56: Middle East & Africa Guillain-Barre Syndrome Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 57: Middle East & Africa Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 58: Middle East & Africa Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 59: Middle East & Africa Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 60: Middle East & Africa Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2023-2031
Figure 61: Middle East & Africa Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 62: Middle East & Africa Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2023-2031